← Eichor
Study identifier: NCT05837052 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC

Condition: Unresectable Lung Non-Small Cell Carcinoma  ·  Sponsor: Zhejiang University

PhasePhase 2
Planned participants49
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This is a phase II, single-arm study to evaluate the efficacy and safety of Serplulimab plus chemotherapy as conversion treatment in patients with stage IIIB-IVA oligometastatic non-small cell lung cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Peng Zhao, MD  ·  +86-18767186629  ·  zhaop@zju.edu.cn

Jian Hu, MD  ·  +86-18767186629  ·  dr_hujian@zju.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Zhejiang UniversityHangzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05837052